Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects

Nazar Farid(Eli Lilly (United States)), D. S. Small(Eli Lilly (United States)), Y. G. Li(Eli Lilly (United States)), Daniel E. Salazar(Daiichi Sankyo (United States)), Kenneth J. Winters(Eli Lilly (United States)), John T. Brandt(Universitätsklinikum Würzburg), Joseph A. Jakubowski(Indiana Biosciences Research Institute), C. Steven Ernest(Metrum Research Group (United States)), Christopher D. Payne(Eli Lilly (United States))
Current Medical Research and Opinion
June 17, 2009
10.1185/03007990903018360
Cited by 34

Related Papers

Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
|American Heart Journal|2006|571
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
|European Heart Journal|2006|537